Stay updated on Gantenerumab in Prodromal Alzheimer's: Clinical Trial

Sign up to get notified when there's something new on the Gantenerumab in Prodromal Alzheimer's: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Gantenerumab in Prodromal Alzheimer's: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study involving the evaluation of the effect of gantenerumab on cognition and functioning in participants with prodromal Alzheimer's Disease.
    Difference
    0.1%
    Check dated 2024-06-06T15:59:01.000Z thumbnail image
  4. Check
    5 days ago
    No Change Detected
  5. Check
    6 days ago
    No Change Detected
  6. Check
    18 days ago
    Change Detected
    Summary
    The change on the webpage now reflects updated participation criteria for researchers looking for individuals with prodromal Alzheimer's disease, aged 50-85, not receiving specific medications, and requiring a study partner for accurate information. The change indicates a focus on specific eligibility criteria for potential study participants.
    Difference
    13%
    Check dated 2024-05-22T08:42:11.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T23:13:32.000Z thumbnail image

Stay in the know with updates to Gantenerumab in Prodromal Alzheimer's: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Gantenerumab in Prodromal Alzheimer's: Clinical Trial page.